AdaptVac ApS: Financial statements 2021
CVR: 38732730
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 1,330,522 and a net result of DKK -1,781,825 compared with DKK 15,460,206 the year before. That is a decrease of 93.4% compared with the year before. Equity in the 2021 report amounted to DKK 12,556,754. The solvency ratio was 82.6%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 1,330,522
- Profit/Loss
- DKK -1,781,825
- Equity
- DKK 12,556,754
- Total Assets
- DKK 15,193,534
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 1.3 mio. | -1.8 mio. | 12.6 mio. | 5 |
| 2020 | - | 20.2 mio. | 15.5 mio. | 15.3 mio. | 3 |
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
| 2018 | - | 432 t. | 334 t. | 64 t. | 0 |
Official annual report
Find more companies like AdaptVac ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
AdaptVac ApS has published its annual report for 2020. Gross profit came to DKK 20,231,326, and the net result was DKK 15,460,206.
As of May 27, 2021, Jacob Hjulmand has joined the board of directors of AdaptVac ApS.
As of May 27, 2021, Bent Ulrich Frandsen has left the board of directors of AdaptVac ApS.
As of February 1, 2021, EXPRES2ION BIOTECHNOLOGIES ApS is registered as an owner of AdaptVac ApS with an ownership share of 33%.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The board consists of Morten Agertoug Nielsen (chair), Adam Frederik Sander Bertelsen, Ali El-Salanti and Jacob Hjulmand. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. According to the 2025 annual report, the company had an average of 7 employees. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity in the 2025 report amounted to DKK 10,808,696.